## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## MEDICAL TECHNOLOGIES EVALUATION PROGRAMME

### **Equality impact assessment – Guidance development**

# Pipeline embolisation device for the treatment of complex intracranial aneurysms

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

#### Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

The scope requested that the natural history of the disease be considered and presented by the sponsor in its submission. No potential equality issues were identified during the scope process.

2. Have any other potential equality issues been highlighted in the manufacturer's submission, or patient organisation questionnaires, and, if so, how has the Committee addressed these?

No potential equality issues have been highlighted.

3. Have any other potential equality issues been identified by the Committee and, if so, how has the Committee addressed these?

No potential equality issues have been highlighted. The Committee considered the natural history of the disease as presented by the sponsor and expert advisers when making its draft recommendations.

4. Do the preliminary recommendations make it more difficult in practice

for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

The preliminary recommendations promote the use of this technology in a specific patient group. However, the consultation document does not restrict access to this technology for other patient groups.

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligations to promote equality?

No equality issues have been identified.

6. Have the Committee's considerations of equality issues been described in the medical technology consultation document, and, if so, where?

No equality issues have been identified.

Approved by Associate Director (name): Mark Campbell

Date: 16 March 2012

### Medical technologies guidance document

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No equality issues have been raised.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups?

If so, what are the barriers to access for the specific group?

The recommendations do not restrict use of this technology.

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

No equalities issues have been identified.

4. Have the Committee's considerations of equality issues been described in the medical technologies guidance document, and, if so, where?

No equalities issues have been identified.

Approved by Programme Director (name): Mirella Marlow

**Date:** 20 March 2012